查詢結果分析
來源資料
頁籤選單縮合
題 名 | Gastrointestinal Stromal Tumor: 2 Cases Report and Review=腸胃基質瘤:兩例病例報告及文獻回顧 |
---|---|
作 者 | 莊伯恒; 鄭企峰; 廖麗瑛; 施麗順; 王朝欣; 黃明哲; | 書刊名 | 內科學誌 |
卷 期 | 13:2 2002.04[民91.04] |
頁 次 | 頁86-93 |
分類號 | 415.5 |
關鍵詞 | 腸胃基質瘤; GISTs; Gastrointestinal stromal tumors; C-kit; STI571(In the U.S.:Gleevec[fef0](imatinib mesylate); Outside the U.S.:Glivec[feb9](imatinib); |
語 文 | 英文(English) |
中文摘要 | 腸胃基質瘤 (GIST) 是指源自於腸胃道的基質細胞瘤 , 是組織基質上的原始細 胞瘤。最近的研究顯示腸胃基質瘤的細胞有一種生長因子受體稱為 c-kit, 是原始 致癌基因 c-kit 的產物 , 具有酥胺酸激酉每 (tyrosine kinase) 的功能。就臨床而 言 , 腸胃基質瘤最具特異性及可運用於臨床的診斷標準是以免疫組織化學法染色能染出c-kit(CD117) 的表現。腸胃基質瘤有必要以能染出腫瘤細胞有廣泛CD-117 為診斷標準來重新分類。我們報告兩位復發性腸胃基質細胞瘤的女性病 人 , 分別以手術治療其復發腫瘤1 及 4 年卻仍有新腫瘤生成。她們分別改用了口 服 STI571(glivec) 的治療。 Glivec 是一種小分子的高度專一性靶標藥物 , 競爭性地抑制細胞膜訊息傳遞酵素 ( 酥胺酸激酉每 ) 的活性。依照過去的使用報告 而言 , 它是非常安全的。我們的這兩位病人有一位腫瘤消失 , 過著正常的生活 , 另一位卻死亡。僅就目前能獲得的文獻來檢視這個結果。 |
英文摘要 | The term GISTs ( gastrointestinal stromal tumors) was introduced as a histogenetically neutral term referring to the main group of mesenchymal tumors of the gastrointestinal tract. Recent studies have shown that cells in GISTs express a growth factor receptor with tyrosine kinase activity termed c-kit, which is the product of the c-kit proto-oncogene. Clinically, the most specific and practicable diagnostic criterion for GISTs is the immunohistochemically determinated c-kit (CD- 117) positive expressionl. Reclassification of GISTs by cell-surface expression of CD- 117 is necessary. We report two cases of refractory GISTs which recurred after surgical intervention, after 1 and 4 years respectively. They received the therapy of ST1571 (glivec /imatinib, Norvatis), a small molecule inhibitor of the kinase domain of c-kit2. Glivec has highly specific target inhibition of tyrosine kinase, with very good safety profile. Out of two patients, one has survived with good health and the other has died. We have reviewed the subject according to literature available. ( J Intern Med Taiwan 2002;13: 86-93 ) |
本系統中英文摘要資訊取自各篇刊載內容。